Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

NRXS

Neuraxis Inc

May 03 • 04:00PM ET

3.21

Dollar change -0.09
Percentage change -2.72	%

Healthcare • Biotechnology • USA • AMEX

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-3.39	Insider Own	53.77%	Shs Outstand	6.51M	Perf Week	-1.23%
Market Cap	21.15M	Forward P/E	-	EPS next Y	-	Insider Trans	-0.00%	Shs Float	3.05M	Perf Month	3.55%
Income	-15.01M	PEG	-	EPS next Q	-	Inst Own	1.93%	Short Float	0.19%	Perf Quarter	32.10%
Sales	2.46M	P/S	8.60	EPS this Y	-	Inst Trans	-	Short Ratio	0.58	Perf Half Y	57.35%
Book/sh	-0.22	P/B	-	EPS next Y	-	ROA	-1469.91%	Short Interest	0.01M	Perf Year	-
Cash/sh	0.01	P/C	264.42	EPS next 5Y	-	ROE	-	52W Range	1.80 - 6.93	Perf YTD	20.22%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-53.68%	Beta	-
Dividend TTM	-	Quick Ratio	0.12	Sales past 5Y	10.42%	Gross Margin	87.67%	52W Low	78.33%	ATR (14)	0.24
Dividend Ex-Date	-	Current Ratio	0.13	EPS Y/Y TTM	-	Oper. Margin	-270.79%	RSI (14)	50.80	Volatility	5.70% 6.00%
Employees	19	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-609.99%	Recom	1.00	Target Price	7.50
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	-2329.46%	Payout	-	Rel Volume	0.66	Prev Close	3.30
Sales Surprise	-66.23%	EPS Surprise	-694.12%	Sales Q/Q	-13.31%	Earnings	Apr 09 AMC	Avg Volume	10.14K	Price	3.21
SMA20	2.19%	SMA50	-2.55%	SMA200	-0.63%	Trades		Volume	6,663	Change	-2.72%

Apr-23-24 09:00AM	NeurAxis Announces New Medical Policy Coverage in North Dakota (GlobeNewswire) -11.18%
Apr-12-24 08:44AM	NeurAxis, Inc. (NASDAQ:NRXS) Q4 2023 Earnings Call Transcript (Insider Monkey)
Apr-09-24 04:05PM	NeurAxis Reports Fourth Quarter and Fiscal Year 2023 Financial Results (GlobeNewswire)
Apr-01-24 04:15PM	NeurAxis to Host Fourth Quarter and Full Year 2023 Results and Business Update Call on Tuesday, April 9, 2024 (GlobeNewswire)
Mar-27-24 09:00AM	NeurAxis Announces IB-Stim Results from a Large, Pediatric, Multi-Center Registry (GlobeNewswire)
09:00AM	Loading…
Mar-11-24 09:00AM	NeurAxis Announces Highmark BCBS Policy Coverage (GlobeNewswire)
Mar-04-24 09:00AM	NeurAxis Announces Blue Cross and Blue Shield of Kansas City Policy Coverage (GlobeNewswire) +8.82%
Feb-27-24 11:00AM	NeurAxis to Present at Oppenheimer 34th Annual Healthcare MedTech & Services Conference (GlobeNewswire)
Jan-31-24 09:00AM	NeurAxis Appoints Timothy Henrichs as Chief Financial Officer (GlobeNewswire)
Dec-20-23 09:00AM	NeurAxis, Inc. Issues Letter to Shareholders from Brian Carrico, President and Chief Executive Officer (GlobeNewswire)
Nov-20-23 05:30PM	NeurAxis Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-15-23 09:00AM	NeurAxis Announces CareFirst BCBS Policy Coverage (GlobeNewswire) +14.17%
Nov-14-23 09:00AM	NeurAxis Secures $3 Million Financing (GlobeNewswire)
Nov-08-23 09:00AM	NeurAxis Signs Exclusive Option Agreement with University of Michigan for Innovative Gastrointestinal Device (GlobeNewswire)
Sep-26-23 09:00AM	NeurAxis Announces Results of Comparative Study of IB-Stim and Standard Medical Therapy in Adolescents with Functional Abdominal Pain Disorders (GlobeNewswire)
08:00AM	Loading…
Sep-21-23 08:00AM	NeurAxis Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Sep-13-23 09:00AM	NeurAxis to Present at the Gilmartin Group Emerging Growth Showcase (GlobeNewswire) +7.87%
Sep-12-23 10:15AM	EXCLUSIVE: NeurAxis' Nerve Field Stimulation Tech Shows Improved Quality of Life of Adolescents Patients With Irritable Bowel Syndrome (Benzinga) -16.92%
09:00AM	NeurAxis Announces Publication of Prospective Study Showing IB-Stim Improves Quality of Life of Adolescents with IBS (GlobeNewswire)
Aug-29-23 09:00AM	NeurAxis Highlights Pediatric Post-Concussion Clinical Study (GlobeNewswire)
Aug-24-23 09:00AM	NeurAxis Highlights Strength of its Board of Directors (GlobeNewswire) -10.15%
Aug-22-23 09:00AM	NeurAxis Highlights Two Independent Studies Showing Benefits of IB-Stim in Adolescents Involving the Gut Microbiome (GlobeNewswire) +16.50%
Aug-17-23 09:02AM	NeurAxis Announces Over $8 Million in IB-Stim Revenue (GlobeNewswire)
Aug-15-23 09:00AM	NeurAxis Announces Positive University of Michigan IB-Stim Cost Effectiveness Study at ANMS 2023 (GlobeNewswire)
Aug-11-23 09:30AM	Goldman Small Cap Research Publishes New Research Report on NeurAxis, Inc. (ACCESSWIRE)
Aug-10-23 09:00AM	NeurAxis Highlights Current Commercial Insurance Coverage with BCBS Massachusetts, BCBS South Carolina, BCBS Nebraska, and Quartz Wisconsin (GlobeNewswire)
09:00AM	Exchange Listing Client, Neuraxis, Inc., Successfully Completes Its Initial Public Offering and NYSE Listing (GlobeNewswire)
Aug-09-23 10:00AM	NeurAxis Announces Pricing of Initial Public Offering (GlobeNewswire)

NeurAxis, Inc. develops neuromodulation therapies to address chronic and debilitating conditions in children. Its product IB-Stim is a non-surgical device that works by sending gentle electrical impulses into cranial nerve bundles located in the ear. The company was founded by Gary Peterson and Christopher Robin Brown in 2011 and is headquartered in Carmel, IN.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hannasch Brian	10% Owner	Dec 28 '23	Sale	2.61	76	198	532,901	Jan 23 04:06 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NRXS

Neuraxis Inc

Upgrade your FINVIZ experience